Skip to content
Screener

Artiva Biotherapeutics, Inc. ARTV Interest Income

Interest Income at other companies

Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
$2.33M-17.6%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$717.17K+377%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$3.65M-38.4%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$4.24M+47.6%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
$5.8M-21.7%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
$3.57M-35.2%

Other financials

Income statement

See full
Revenue-—
Operating income-$26.9M-17.9%
Net income-$25.0M-17.6%
EPS (diluted)-$0.63+27.6%

Balance sheet

See full
Cash & equivalents$301.9M+944%
Total debt$9.8M-25.5%
Total equity$347.5M+133%
Total assets$368.6M+118%

Cash flow

See full
Operating cash flow-$20.4M+11.4%
CapEx$415.0K-60.7%
Free cash flow-$20.8M+13.6%

Valuation

See full
Market cap$548.55M+780%
Enterprise value$256.48M+450%

Profitability

See full
Operating margin-83.9%—
Net margin-79.3%—

Returns & leverage

See full
Return on equity-36.6%—
Debt / equity0×-0.1×
Current ratio24.2×+10.3×

Where this comes from

Reported directly by Artiva Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeNet.

The source filing: Artiva Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-338029
Line itemTHREE MONTHS ENDED JUNE 30, 2026THREE MONTHS ENDED JUNE 30, 2025SIX MONTHS ENDED JUNE 30, 2026SIX MONTHS ENDED JUNE 30, 2025
Total operating expenses26,89022,81051,32044,982
Loss from operations(26,890)(22,810)(51,320)(44,982)
Other income, net:
Interest income1,8861,5612,7983,425
Other (expense) income, net(1)(5)1(8)
Total other income, net1,8851,5562,7993,417
Net loss$(25,005)$(21,254)$(48,521)$(41,565)
Net loss per share, basic and diluted$(0.63)$(0.87)$(1.51)$(1.71)

Item 1. Financial Statements

FAQ

What is Artiva Biotherapeutics, Inc.'s interest income?
Artiva Biotherapeutics, Inc. (ARTV) reported interest income of $1.89M in Q2 2026.
How has Artiva Biotherapeutics, Inc.'s interest income changed year-over-year?
Artiva Biotherapeutics, Inc.'s interest income increased by 20.8% year-over-year, from $1.56M to $1.89M.
What is the long-term trend for Artiva Biotherapeutics, Inc.'s interest income?
Over 2 years (2023 to 2025), Artiva Biotherapeutics, Inc.'s interest income has grown at a 53.3% compound annual growth rate (CAGR), from $2.54M to $5.96M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.

Ask your AI about Artiva Biotherapeutics, Inc.'s interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude